List view / Grid view
Genomics is the branch of molecular biology concerned with the structure, function, evolution, and mapping of genomes.
This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how neoantigens of cancer cells could be used as the basis of novel immuno-oncology vaccines.
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
The researchers revealed the mechanism by which signalling becomes dysfunctional in upper motor neuron (UMN) diseases, such as amyotrophic lateral sclerosis (ALS).
Post-infection genome editing could be the cause of mutations in the SARS-CoV-2 virus responsible for the COVID-19 pandemic, driving its evolution.
A new paper describes the first full study of the epigenetics of human tumour organoids, suggesting this could be used to develop novel oncology treatments.
Russian researchers have created a process for the development of mouse models for use in pre-clinical studies of COVID-19 treatments and vaccines.
After analysing the genomic diversity in SARS-CoV-2 by screening over 7,500 viruses from infected patients, researchers have offered clues for COVID-19 drug development.
Next-generation sequencing has revealed an 81-base pair mutation of the SARS-CoV-2 virus, which could be used to develop new antivirals or vaccines.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
Researchers have unravelled the viral transcriptome and translatome of the herpes simplex virus (HSV-1) to aid disease research and immunotherapy.
Induced pluripotent stem cells made to produce insulin and CRISPR, used to correct a genetic defect, cured Wolfram syndrome in mice.
Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
Researchers discovered the monoclonal antibodies of a convalescent Marburg infection patient bound to the glycoprotein and combatted infection in two novel ways.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
